Clinical trials: Headaches
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study
Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and…
- Trial name
- NCT02901756
- Testing
- Antemig
- Volunteers
- 132 people
- Sponsor
- PiLeJe
Migraine
Effectiveness of a Dialogue-based Online Intervention Against Migraine
This trial was designed to evaluate the effectiveness of a dialogue-based online intervention (ceprica) that provides information regarding cognitive behavioural therapy (CBT) in patients with migraine.
- Trial name
- EU-OPTMi (NCT04276142)
- Testing
- ceprica (additional to treatment as usual), active control intervention (additional to treatment as usual)
- Where
- Germany
- Volunteers
- 321 people
- Sponsor
- Gaia AG
Migraine
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC) administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic migraine (EM).
- Trial name
- HALO (NCT02638103)
- Testing
- Fremanezumab
- Where
- 139 sites in United States, Canada and 7 more
- Volunteers
- 1,890 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
- Trial name
- NCT03934086
- Testing
- rimegepant
- Sponsor
- Pfizer
Migraine
Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)
Migraine is a prevalent neurological disorder that severely impacts both children and adolescents, causing significant disability.
- Trial name
- NCT06138756
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 293 people
- Sponsor
- Theranica
Migraine
A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults
PF-05180999 is a novel phosphodiesterase-2 (PDE2) inhibitor. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of PF-05180999 administered twice daily over 14 days.
- Trial name
- NCT01981486
- Testing
- PF-05180999 Tablets
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Cluster Headache, Episodic
Eptinezumab in Participants With Episodic Cluster Headache
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
- Trial name
- ALLEVIATE (NCT04688775)
- Testing
- Eptinezumab
- Where
- 120 sites in United States, Belgium and 17 more
- Volunteers
- 231 people
- Sponsor
- H. Lundbeck A/S
Migraine Disorders
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
- Trial name
- NP101-011 (NCT00723983)
- Testing
- Sumatriptan succinate, NP101 Study Patch
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NuPathe Inc.
Migraine
Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)
This study will demonstrate the definitive bioequivalence of a solid dose formulation of MK0974 to the liquid filled capsule formulation of MK0974.
- Trial name
- NCT00966030
- Testing
- MK0974 tablet, Comparator: MK0974 liquid filled capsule
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM.
- Trial name
- NCT00475514
- Testing
- Frovatriptan 2.5mg QD, Frovatriptan 2.5 mg BID
- Volunteers
- 500 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.
- Trial name
- NCT00095004
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment: 1day
- Volunteers
- 167 people
- Sponsor
- Organon and Co
Chronic Migraine
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT04829747
- Testing
- Atogepant
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- Allergan
Myofascial Pain Syndrome - Lower Back, Myofascial Pain Syndrome - Neck
Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome
Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain…
- Conditions
- Myofascial Pain Syndrome - Lower Back, Myofascial Pain Syndrome - Neck, Myofascial Pain Syndrome - Tension Headache
- Trial name
- NCT05851326
- Testing
- Active Sonodyn
- Where
- 6 sites in Austria, Switzerland
- Volunteers
- 126 people
- Sponsor
- Sobet AG
Acute Migraine
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
This trial is to evaluate the long-term safety and tolerability of Rimegepant 75mg ODT in Chinese subjects with migraine
- Trial name
- NCT05371652
- Testing
- Rimegepant 75mg Orally Disintegrating Tablets (ODT)
- Where
- 26 sites in China
- Volunteers
- 241 people
- Sponsor
- Pfizer
Migraine
Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT07304518
- Testing
- PRT-064040 nasal spray
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Migraine With Aura, Migraine Without Aura
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.
- Trial name
- NCT00334178
- Testing
- Laxymig ER (drug)
- Where
- 7 sites in Taiwan
- Volunteers
- 74 people
- Sponsor
- Lotus Pharmaceutical
Migraine
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
- Trial name
- NCT00632385
- Testing
- Eletriptan
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.